{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:30:15Z","timestamp":1794022215615,"version":"4.8.0"},"reference-count":142,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2016,9,6]]},"abstract":"<jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their unique glycosuric mechanism, SGLT2 inhibitors also reduce weight. Perhaps more important are the osmotic diuretic and natriuretic effects contributing to plasma volume contraction, and decreases in systolic and diastolic blood pressures by 4 to 6 and 1 to 2 mm\u2009Hg, respectively, which may underlie cardiovascular and kidney benefits. SGLT2 inhibition also is associated with an acute, dose-dependent reduction in estimated glomerular filtration rate by \u22485 mL\u00b7min<jats:sup>\u20131<\/jats:sup>\u00b71.73 m<jats:sup>\u20132<\/jats:sup>and \u224830% to 40% reduction in albuminuria. These effects mirror preclinical observations suggesting that proximal tubular natriuresis activates renal tubuloglomerular feedback through increased macula densa sodium and chloride delivery, leading to afferent vasoconstriction. On the basis of reduced glomerular filtration, glycosuric and weight loss effects are attenuated in patients with chronic kidney disease (estimated glomerular filtration rate &lt;60 mL\u00b7min<jats:sup>\u20131<\/jats:sup>\u00b71.73 m<jats:sup>\u20132<\/jats:sup>). In contrast, blood pressure lowering, estimated glomerular filtration rate, and albuminuric effects are preserved, and perhaps exaggerated in chronic kidney disease. With regard to long-term clinical outcomes, the EMPA-REG OUTCOME trial (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes) in patients with type 2 diabetes mellitus and established cardiovascular disease randomly assigned to empagliflozin versus placebo reported a 14% reduction in the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and &gt;30% reductions in cardiovascular mortality, overall mortality, and heart failure hospitalizations associated with empagliflozin, even though, by design, the hemoglobin A1c difference between the randomized groups was marginal. Aside from an increased risk of mycotic genital infections, empagliflozin-treated patients had fewer serious adverse events, including a lower risk of acute kidney injury. In light of the EMPA-REG OUTCOME results, some diabetes clinical practice guidelines now recommend that SGLT2 inhibitors with proven cardiovascular benefit be prioritized in patients with type 2 diabetes mellitus who have not achieved glycemic targets and who have prevalent atherosclerotic cardiovascular disease. With additional cardiorenal protection trials underway, sodium-related physiological effects of SGLT2 inhibitors and clinical correlates of natriuresis, such as the impact on blood pressure, heart failure, kidney protection, and mortality, will be a major management focus.<\/jats:p>","DOI":"10.1161\/circulationaha.116.021887","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T03:33:17Z","timestamp":1469763197000},"page":"752-772","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1311,"title":["Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus"],"prefix":"10.1161","volume":"134","author":[{"given":"Hiddo J.L.","family":"Heerspink","sequence":"first","affiliation":[{"name":"From Department of Clinical Pharmacy &amp; Pharmacology, University of Groningen, University Medical Center Groningen, Netherlands (H.J.L.H.); Department of Medicine, Division of Endocrinology, Mount Sinai Hospital, University of Toronto, ON, Canada (B.A.P.); Department of Medicine, Division of Cardiology, St. Michael\u2019s Hospital, University of Toronto, ON, Canada (D.H.F.); Ted Rogers Centre for Heart Research and Department of Medicine, Division of Cardiology, Peter Munk Cardiac Centre, Toronto..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Perkins","sequence":"additional","affiliation":[{"name":"From Department of Clinical Pharmacy &amp; Pharmacology, University of Groningen, University Medical Center Groningen, Netherlands (H.J.L.H.); Department of Medicine, Division of Endocrinology, Mount Sinai Hospital, University of Toronto, ON, Canada (B.A.P.); Department of Medicine, Division of Cardiology, St. Michael\u2019s Hospital, University of Toronto, ON, Canada (D.H.F.); Ted Rogers Centre for Heart Research and Department of Medicine, Division of Cardiology, Peter Munk Cardiac Centre, Toronto..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Fitchett","sequence":"additional","affiliation":[{"name":"From Department of Clinical Pharmacy &amp; Pharmacology, University of Groningen, University Medical Center Groningen, Netherlands (H.J.L.H.); Department of Medicine, Division of Endocrinology, Mount Sinai Hospital, University of Toronto, ON, Canada (B.A.P.); Department of Medicine, Division of Cardiology, St. Michael\u2019s Hospital, University of Toronto, ON, Canada (D.H.F.); Ted Rogers Centre for Heart Research and Department of Medicine, Division of Cardiology, Peter Munk Cardiac Centre, Toronto..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Husain","sequence":"additional","affiliation":[{"name":"From Department of Clinical Pharmacy &amp; Pharmacology, University of Groningen, University Medical Center Groningen, Netherlands (H.J.L.H.); Department of Medicine, Division of Endocrinology, Mount Sinai Hospital, University of Toronto, ON, Canada (B.A.P.); Department of Medicine, Division of Cardiology, St. Michael\u2019s Hospital, University of Toronto, ON, Canada (D.H.F.); Ted Rogers Centre for Heart Research and Department of Medicine, Division of Cardiology, Peter Munk Cardiac Centre, Toronto..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z. I.","family":"Cherney","sequence":"additional","affiliation":[{"name":"From Department of Clinical Pharmacy &amp; Pharmacology, University of Groningen, University Medical Center Groningen, Netherlands (H.J.L.H.); Department of Medicine, Division of Endocrinology, Mount Sinai Hospital, University of Toronto, ON, Canada (B.A.P.); Department of Medicine, Division of Cardiology, St. Michael\u2019s Hospital, University of Toronto, ON, Canada (D.H.F.); Ted Rogers Centre for Heart Research and Department of Medicine, Division of Cardiology, Peter Munk Cardiac Centre, Toronto..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj0251128"},{"issue":"3","key":"e_1_3_4_3_2","first-page":"F459","article-title":"Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter.","volume":"263","author":"Wells RG","year":"1992","unstructured":"Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol. 1992;263(3 pt 2):F459\u2013F465.","journal-title":"Am J Physiol"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0052"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.87"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.12.3427"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2391"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00518.2013"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114563304"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12307"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00007"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12214"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009417"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70208-0"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12090"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70120-2"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12459"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-3055"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1237"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.72.3.243"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/719578"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.919907"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12500"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1174841"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0049"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2338"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/846807"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.34.4.843"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.51"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814544153"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.01.007"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.12.038"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","unstructured":"Perkins BA Udell JA Cherney DZ. No need to sugarcoat the message: is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis? [published online ahead of print March 30 2016] Am J Kidney Dis.. doi: 10.1053\/j.ajkd.2016.03.410. http:\/\/www.ajkd.org\/article\/S0272-6386(16)00639-9\/abstract. Accessed August 11 2016.","DOI":"10.1053\/j.ajkd.2016.03.410"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2016.2"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12747"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1096"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000871"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.02.022"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00417-9"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.3109\/08037051.2015.1116258"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12436"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00113.2003"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(78)90303-4"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12278"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12322"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-015-9471-1"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0730-0"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0850"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.10.061"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2009.04.010"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.12.041"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-14-23"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0773"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.133801"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-28"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12572"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.246"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00457-X"},{"key":"e_1_3_4_68_2","first-page":"A265 [1030-P]","article-title":"Empagliflozin has no discernible effect on muscle sympathetic nerve activity in patients with type 2 diabetes despite reductions in blood pressure and weight.","volume":"63","author":"Jordan J","year":"2014","unstructured":"Jordan J, Tank J, Heusser K, Heise T, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC. Empagliflozin has no discernible effect on muscle sympathetic nerve activity in patients with type 2 diabetes despite reductions in blood pressure and weight. Diabetes. 2014;63:A265 [1030-P].","journal-title":"Diabetes"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000094221.86888.AE"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3547-2"},{"key":"e_1_3_4_71_2","unstructured":"FDA Briefing Document. NDA 204042. Invokana (canagliflozin) Tablets. Endocrinologic and Metabolic Drugs Advisory Committee Meeting January 10. 2013. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM334550.pdf. Accessed May 10 2016."},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.017923"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12188"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112521"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1268-0"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2189"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.79"},{"issue":"6","key":"e_1_3_4_79_2","first-page":"F946","article-title":"Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus.","volume":"260","author":"Pollock CA","year":"1991","unstructured":"Pollock CA, Lawrence JR, Field MJ. Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus. Am J Physiol. 1991;260(6 pt 2):F946\u2013F952.","journal-title":"Am J Physiol"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00232-001-0036-y"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114700"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00031.2005"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V10122569"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/305403"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00357.2011"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000084"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703829"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203869"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054442"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/542042"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00409.2012"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0612"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0029"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005080872"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2008.01.010"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1159\/000208211"},{"key":"e_1_3_4_97_2","article-title":"The effect of SGLT2 inhibition on adenosine excretion in patients with type 1 diabetes.","author":"Rajasekeran H","year":"2016","unstructured":"Rajasekeran H, Lytvyn Y, Bozovic A, Lovshin J, Diamandis E, Cattran D, Husain M, Advani A, Perkins B, Reich HN, Kulasingam V, Cherney DZI. The effect of SGLT2 inhibition on adenosine excretion in patients with type 1 diabetes. Poster No: X. Presented at the American Diabetes Association (ADA) 76th Scientific Sessions. 2016.","journal-title":"Poster No: X. Presented at the American Diabetes Association (ADA) 76th Scientific Sessions"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.2010.02147.x"},{"key":"e_1_3_4_99_2","first-page":"23","article-title":"Lithium clearance in the evaluation of segmental renal tubular reabsorption of sodium and water in diabetes mellitus.","volume":"41","author":"Sk\u00f8tt P","year":"1994","unstructured":"Sk\u00f8tt P. Lithium clearance in the evaluation of segmental renal tubular reabsorption of sodium and water in diabetes mellitus. Dan Med Bull. 1994;41:23\u201337.","journal-title":"Dan Med Bull"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137163"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12654"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4008-2"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111732"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V481564"},{"issue":"2","key":"e_1_3_4_105_2","first-page":"R572","article-title":"Atrial natriuretic peptide and glomerular hyperfiltration during onset of spontaneous diabetes mellitus.","volume":"266","author":"Okwueze MI","year":"1994","unstructured":"Okwueze MI, Opgenorth TJ, von Geldern TW, Vari RC. Atrial natriuretic peptide and glomerular hyperfiltration during onset of spontaneous diabetes mellitus. Am J Physiol. 1994;266(2 pt 2):R572\u2013R577.","journal-title":"Am J Physiol"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113120"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400721"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2005.01497.x"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.41.8.936"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.1159\/000187213"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00555.2014"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","unstructured":"Wang Y Xu L Yuan L Li D Zhang Y Zheng R Liu C Feng X Li Q Li Q Ma J. Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed type 2 diabetes [published online ahead of print March 1 2016]. Diabetic Med. doi: 10.1111\/dme.13107. http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13107\/abstract;jsessionid=DF7B8C6AA38E5B2712D828E6F82976BF.f04t03. Accessed August 11 2016.","DOI":"10.1111\/dme.13107"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2014.10.013"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_3_4_115_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12073"},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv728"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.18574"},{"key":"e_1_3_4_119_2","first-page":"CD003838","article-title":"Diuretics for heart failure.","author":"Faris R","year":"2006","unstructured":"Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. Cochrane Database Syst Rev. 2006:CD003838.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62070-5"},{"key":"e_1_3_4_121_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212914"},{"key":"e_1_3_4_122_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1470-0"},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.58"},{"key":"e_1_3_4_124_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0355"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12578"},{"key":"e_1_3_4_126_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130658"},{"key":"e_1_3_4_127_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3828"},{"key":"e_1_3_4_128_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.091215"},{"key":"e_1_3_4_129_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12585"},{"key":"e_1_3_4_130_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.32.3.307"},{"key":"e_1_3_4_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2014.11.005"},{"key":"e_1_3_4_132_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.45.3.534"},{"key":"e_1_3_4_133_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0031-6997(25)06576-7","article-title":"Glucagon and the circulation.","volume":"35","author":"Farah AE","year":"1983","unstructured":"Farah AE. Glucagon and the circulation. Pharmacol Rev. 1983;35:181\u2013217.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_4_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(96)00214-8"},{"key":"e_1_3_4_135_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196408272710908"},{"key":"e_1_3_4_136_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V10112382"},{"key":"e_1_3_4_137_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303154"},{"key":"e_1_3_4_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61236-2"},{"key":"e_1_3_4_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(03)00213-0"},{"key":"e_1_3_4_140_2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.20452\/pamw.504","article-title":"Intensive glucose control and cardiovascular disease in type 2 diabetes\u2013should we change the recommended target for glycated hemoglobin? Commentary to ACCORD and ADVANCE trials.","volume":"118","author":"Gaede P","year":"2008","unstructured":"Gaede P. Intensive glucose control and cardiovascular disease in type 2 diabetes\u2013should we change the recommended target for glycated hemoglobin? Commentary to ACCORD and ADVANCE trials. Pol Arch Med Wewn. 2008;118:619\u2013621.","journal-title":"Pol Arch Med Wewn"},{"key":"e_1_3_4_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2013.01.021"},{"key":"e_1_3_4_142_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"e_1_3_4_143_2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487315569401"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.116.021887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T08:41:02Z","timestamp":1749026462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.116.021887"}},"subtitle":["Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications"],"short-title":[],"issued":{"date-parts":[[2016,9,6]]},"references-count":142,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,9,6]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.116.021887"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.116.021887","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,6]]},"assertion":[{"value":"2016-07-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}